Doximity, Inc. (DOCS): one to watch?

Cheap and debt-free, but growth has structurally slowed because Doximity's pharma-ad customers are pulling back spending — not yet resolved.

👀 WATCH Fundamentals74/100

Down 74% from its all-time high of $102.02 — now $26.35

Why DOCS dropped

Doximity's stock has been stuck near its lows because its main revenue source — advertising paid for by pharmaceutical companies — has become unpredictable, and the company just guided next year's revenue below what Wall Street expected while ramping up AI spending, which hurt near-term profits.

Fwd P/E 17.0Op margin 21.5%Rev growth 7.3%Debt/equity 1.1%Analyst upside 13.0%

How this scored 74/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 25.5%

✅ Generates cash Free cash flow $240M

✅ Not drowning in debt Debt/equity 1.1% (limit 200%)

✅ Can pay its bills Current ratio 6.1 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 21/25

Operating margin 21.5% 8/9

Net profit margin 25.5% 8/8

Return on equity 17.2% 5/8

Growth Is it getting bigger, or dying? 12/25

Revenue growth 7.3% 4/9

Earnings growth -51.9% 0/8

Expected profit change 84.4% 8/8

Value Is it cheap right now? 16/25

Forward P/E 17.0 7/10

PEG ratio 0.6 8/8

Analyst target upside 13.0% 2/7

Balance sheet Will it survive? 25/25

Debt / equity 1.1% 10/10

Current ratio 6.1 8/8

Free cash flow $240M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for DOCS — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-09-08. Research only — not financial advice.